Oncology & Cancer

Physicians classify brain tumors and determine treatment options, in part, by the genes they express. According to World Health Organization standards, the abnormal activation of oncogene FOXR2 only occurs in central nervous system (CNS) neuroblastoma, but that may not be true. Findings from St. Jude Children’s Research Hospital show FOXR2 activation in multiple pediatric CNS tumor types, mostly brain tumors, with significantly different clinical outcomes.

A Ludwig Cancer Research study has identified a novel strategy for treating acute myelogenous leukemia (AML), an aggressive blood cancer for which the median survival time following diagnosis remains just 8.5 months.

A multinational research team of clinicians and scientists from South Korea and Singapore has published positive findings from a phase 2 clinical trial for a new combination therapy for an aggressive, Asian-prevalent blood cancer, extranodal NK/T-cell lymphoma.

A recent study published in the American Journal of Gastroenterology investigates the incidence and survival rates of colorectal cancer (CRC) in the U.K. The research offers health care decision-makers crucial insights for planning, management and screening for colorectal cancer.

It is well known that men are reluctant to see a doctor, especially a urologist. As a result, there is a risk that prostate cancer will be detected too late. A simple urine test may be able to minimize this risk in the future. This test is being developed by the spin-off ONTRACK Biomedical.

New research from the Centenary Institute has found that switching off a specific protein in liver cells may help prevent the early development of liver cancer.

A cruel consequence of advanced cancer is the profound apathy many patients experience as they lose interest in once-cherished activities. This symptom is part of a syndrome called cachexia, which affects about 80% of late-stage cancer patients, leading to severe muscle wasting and weight loss that leave patients bone thin despite adequate nutrition.

New research has revealed that Schistosoma haematobium (S. haematobium), a parasitic infection affecting millions globally, can trigger cancer-related gene activity in the cervical lining, with changes becoming even more pronounced after treatment. Presented at ESCMID Global 2025, this study sheds new light on how this often-overlooked parasitic disease may contribute to cervical cancer risk at the molecular level.

Researchers at Moffitt Cancer Center have found that tapping into the body’s own immune system and activating a type of immune cell known as B cells, could be the key to boosting the effectiveness of tumor-infiltrating lymphocyte, or TIL therapy. Results of their study were published in the Journal for Immunotherapy of Cancer.

Treatment resistance and relapse in the most common type of lung cancer can be traced to a protein called agrin, according to a preclinical study led by Roswell Park Comprehensive Cancer Center. Results of the study, led by Sayan Chakraborty, Ph.D., Assistant Professor of Oncology, Department of Pharmacology & Therapeutics at Roswell Park, have been published in the journal Advanced Science.